• Latin America

    EPIDEMIOLOGY

    Global Information

    • Toxocariasis is found globally, but the majority of cases occur where dogs and cats (often household pets) are kept in close proximity to humans.
    • Ocular toxocariasis is more prevalent in warmer climates because development of infectious Toxocara eggs occurs above 50°F (10°C).
    • The seroprevalence of Toxocara infection has been estimated to be 4%–31% in developed countries and may increase to 86% in tropical regions, where environmental conditions favor the transmission of geohelminths.
    • Despite the high prevalence of Toxocara infections in some areas, little epidemiological information exists on the prevalence of ocular toxocariasis.

    Regional Information (Latin America)

    Sero-prevalence of Toxocariasis species in Latin America

    Argentina

    10.6 – 42.8%

    Bolivia

    27%

    Brazil

    5.5 – 40%

    Chile

    2.2%

    Colombia

    47.5%

    Cuba

    5.2%

    Ecuador

    30%

    Peru

    7.3 – 44.9%

    Trinidad

    27.2 – 62.3%

    Uruguay

    16.1%

    Venezuela

    1.8 – 34.9%

    DIFFERENTIAL DIAGNOSIS

    • Retinoblastoma (Figure 1)
    • Traumatic, bacterial, fungal endophthalmitis (Figure 2)
    • Coats disease (Figure 3)
    • Familial exudative vitreoretinopathy
    • Persistent fetal vasculature (PFV) (Figure 4)
    • Other causes of pars planitis (Figure 5)
    • Toxoplasmosis (Figure 6)
    • Retinopathy of prematurity (ROP) (Figure 7)
    • Combined hamartoma of the retina and retinal pigment epithelium (RPE)
    • Diffuse unilateral subacute neuroretinitis (DUSN)

    PATHOPHYSIOLOGY/DEFINITION

    • Ocular toxocariasis is an uncommon disease that affects mostly children and young adults, resulting in significant vision loss. (Figure 8)
    • It results from  tissue invasion by the second-stage larvae of two intestinal roundworms: Toxocara canis (a common parasite of dogs) and Toxocara cati (a common parasite of cats).
    • Humans acquire the infection as accidental hosts by ingesting soil contaminated with Toxocara eggs (geophagia), ingestion of contaminated food, or the oral-fecal route; the roundworm parasites complete their life cycles in the small intestines of dogs and cats; maturation of the adult worm does not occur in humans.

    Pathogenesis

    • Disease can present as immediate-type and delayed-type hypersensitivity responses, depending on tissue type and host damage. (Figure 9)
    • Commonly affected tissues: liver, lungs, and central nervous system (visceral larvae migrans or VLM), and the eyes (ocular larvae migrans or OLM)
      • VLM and OLV rarely present simultaneously.
    • In OLM, larvae migrate to the eye through: (1) the central retinal artery reaching the posterior pole, (2) the long ciliary arteries, or (3) the vitreous reaching the pars plana, producing inflammation and formation of granuloma.
      • OLM is usually unilateral.

    SIGNS/SYMPTOMS

    Diagnosis of ocular toxocariasis is based on clinical findings (Table 1). OLM generally affects children between 2 and 10 years old, presenting as unilateral decreased visual acuity with or without strabismus. If clinical suspicion of ocular toxocariasis arises, the examiner should attempt to elicit a history of exposure to puppies and soil.

    Characteristic findings:

    • Pain
    • Photophobia
    • Decreased vision
    • Floaters
    • Leukocoria (late-stage disease) 25% of cases (Figure 10)
    • Strabismus
    • Posterior pole granuloma 25% of cases (Figure 11)
    • Peripheral granuloma with or without traction bands 50% of cases (Figure 12)
    • Pars planitis
    • Vitritis
    • Active chorioretinitis
    • Retinal detachment

    Table 2. Clinical Presentations of Ocular Toxocariasis  

    Clinical
    Syndrome

    Age of Onset

    Characteristic
    Findings

    Chronic endophthalmitis

    2–9

    Anterior uveitis and vitritis
    Possible peripheral granuloma or grayish-white exudates near pars plana

    Posterior pole granuloma

    6–14

    Round, yellow-white solid granuloma in macula or peripapillary region (Figure 13) as above
    Minimal or absent intraocular inflammation

    Peripheral granuloma

    6–40

    Peripheral granuloma/mass with dense connective tissue bands in the vitreous that extend from the lesion to the posterior pole. (Figure 14) as above

    LABORATORY EVALUATION

    • Enzyme linked immunosorbent assay (ELISA)
    • serum titer of 1:8 is 91% sensitive and 90% specific for previous exposure

    MANAGEMENT/TREATMENT

    Medical and surgical therapies are used to treat this condition. The goal of treatment is foremost vision preservation, as the prognosis for visual recovery is typically guarded.

    • Medical therapy
      • First line treatment: 5-day course of albendazole (10 mg/kg/day)
      • Second line treatment: Consider other benzimidazoles (mebendazole, tiabendazole, or diethylcarbamazine)
        • Note: Ivermectin has not shown significant efficacy for the treatment of T cani or T cati
      • Consider systemic or periocular corticosteroids to suppress the immune response and limit structural complications of the disease at a rate of 0.5 to 1 mg/kg/day
      • If inflammation persists and the disease appears to be progressing, surgical therapy should be considered.
    • Surgical therapy
      • Pars plana vitrectomy
        • No definitive protocols on treatment.
        • Methods include all variations of vitrectomy (use of SF-6 gas or silicon oil, with or without scleral buckle/lens extraction).
      • Perfluorocarbon liquids injection
        • Indicated to facilitate removal of epiretinal membranes (ERMs) and the posterior hyaloid in cases of tractional retinal detachment.
      • Cryotherapy
        • Applied directly at the areas of exudation at the pars plana with a double freeze-thaw technique.
      • Endolaser
        • Indicated for treatment of ocular granulomas
    • Prognosis
      • Visual acuity recovery is directly related to the anatomical location of the lesions, the degree of retinal detachment, and compromise of the photoreceptors, external limiting membrane, and optic nerve. Vision loss can therefore be variable, from mild to severe.  
      • Early treatment should be performed to decrease complications and provide better visual outcomes.
      • Most cases of ocular toxocariasis have visual acuity of less than 20/40 at presentation.
      • As in any pediatric condition that affects one eye, amblyopia treatment is an important component of the overall visual rehabilitation scheme.

    CASE STUDY

    Age

    • 6 years old

    Gender

    • Female

    History of Present Illness

    • Blurring of vision in right eye for 2 days prior to admission that has progressively worsened. She also complained of right eye discomfort, redness, and pain 1 day after the onset of illness.
    • Denies any eye discharges, trauma, or foreign body from/to the right eye. There is a history of contact with neighborhood dogs. Denies history of fever, skin rashes, or upper respiratory tract infection symptoms. No previous history of eye diseases and no history of similar conditions among family members.

    Physical Exam

    • Vital signs stable and afebrile. Systemic examination was unremarkable except for palpable lymph nodes in the submandibular region.

    Visual Exam

    • Right eye: injected and nonreactive with corneal edema and mildly dilated pupils. Visual acuity was Hand Motions at 1 foot.
    • Left eye: unremarkable. Best corrected visual acuity was 20/20
    • Ocular echography confirmed the presence of chronic endophthalmitis and exotropia of the right eye (Figure 15).
    • Retinal exam demonstrated a temporal-peripapillary granuloma with tractional retinal detachment and dragged retina (Figure 16A).

    Management/Treatment

    • Toxocara canis IgG was confirmed in vitreous sample in a concentration of 1/256.
    • Pars plana vitrectomy was performed with release of traction and improvement of the retinal anatomy (Figure 16B).
    • Post-operative visual acuity in the right eye remained Hand Motions.

    IMAGE LIBRARY


    Figure 1
    . Retinoblastoma.  (© 2013 American Academy of Ophthalmology)


    Figure 2.  Endophthalmitis.  (© 2013 American Academy of Ophthalmology)



    Figure 3. Coats disease.   (© 2013 American Academy of Ophthalmology)


    Figure 4.
      PHPV retrolental membrane.  (© 2013 American Academy of Ophthalmology)


    Figure 5
    .  Pars planitis.   (© 2013 American Academy of Ophthalmology)


    Figure 6
    .  Toxoplasmosis.  (© American Academy of Ophthalmology)


    Figure 7.
       Retinopathy of Prematurity (ROP).   (© 2013 American Academy of Ophthalmology)


    Figure 8
    .  Ocular Toxocariasis.  (© American Academy of Ophthalmology.  Courtesy of Paul Griggs, MD.)

     
    Figure 9. Toxocariasis pathogenesis and life cycle. Reproduced, with permission, from Clin Microbial Rev . 2003; 16(2): 265-272, and CDC


    Figure 10
    .  Toxocariasis: leukocoria. (© 2014 American academy of Ophthalmology)


    Figure 11
    .  Toxocariasis: macular granuloma. (© 2014 American Academy of Ophthalmology)


    Figure 12.
      Toxocariasis: peripheral granuloma.  (©2014 American Academy of Ophthalmology.)

     


    Figure 13. Toxocara posterior pole granuloma causing macular pucker and tractional retinal detachment in a 9-year-old girl; visual acuity 20/200.  (© American Academy of Ophthalmology. Courtesy of Ramana S. Moorthy, MD.)



    Figure 14. Superotemporal Toxocara peripheral granuloma of left eye with associated tractional retinal detachment and retinal fold through macula. (© 2014 American Academy of Ophthalmology. Courtesy of Ramana S. Moorthy, MD.)



    Figure 15.
    Chronic endophthalmitis seen in ocular echography. (© American Academy of Ophthalmology.)

     


    Figure 16A, 16B.
    Fundus photograph before (A) and after (B) pars plana vitrectomy. A. Temporal-peripapillary granuloma with tractional retinal detachment and dragged retina. B. Traction release and restoration of the retinal anatomy after pars plana vitrectomy. (© 2014 American Academy of Ophthalmology.)

    REFERENCES

    Agudelo C, Villareal E, Cáceres E, López C, Eljach J, Ramírez N, et al. Human and dogs Toxocara canis infection in a poor neighborhood in Bogota. Memórias do Instituto Oswaldo Cruz. Xxxxxxx;1990: 75–78.
    Alabiad CR, Albini TA, Santos CI, Davis JL. Ocular Toxocariasis in a Seronegative Adult. Ophthalmic Surgery, Lasers & Imaging (official journal of the International Society for Imaging in the Eye). 2010; April 2; 1–3.
    Amin HI, McDonald HR, Han DP, Jaffe GJ, Johnson MW, Lewis H, Lopez PF, Mieler WF, Neuwirth J, Sternberg P Jr, Werner JC, Ai E Jr. Vitrectomy update for macular traction in ocular toxocariasis. Retina. 2000; 20(1): 80–85.
    Archelli S, Kozubsky L. Toxocara y Toxocariosis. Acta Bioquím Clín Latinoam. 2008; 42(3): 379–384.
    Arevalo JF, Espinoza J V, Arevalo FA. Ocular toxocariasis. J Ped Ophthalmol and Strabismus. 2013; 50(2): 76–86.
    Arevalo JF, Garcia-amaris RA. The role of vitreo-retinal surgery in children with uveitis. Intl Ophthalmol Clin. 2008; 48(3): 153–172.
    Caumes E. Treatment of cutaneous larva migrans and Toxocara infection. Fundamental & Clin Pharmacology. 2003; 17(2): 213–216.
    Chieffi PP, Vieira dos SS, De Queiroz ML, Lescano SAZ. Human toxocariasis: contribution by Brazilian researchers. Revista do Instituto de Medicina Tropical de São Paulo. 2009; 51(6): 301–308.
    Delgado O, Rodríguez-morales AJ. Aspectos clínico-epidemiológicos de la toxocariasis: una enfermedad desatendida en Venezuela y América Latina. Boletín de malariología y salud ambiental. 2009; 49(1): 1–33.
    Despommier D. Toxocariasis: Clinical aspects, epidemiology, medical ecology, and molecular aspects. 2003; 16(2). [Au: Pls provide name of journal and page numbers.]
    De Visser L, Rothova A, De Boer JH, Van Loon AM, Kerkhoff FT, Canninga-van Dijk MR, et al. Diagnosis of ocular toxocariasis by establishing intraocular antibody production. Am  J Ophthalmol. 2008; 145(2): 369–374.
    Espinoza YA, Huapaya PH, Roldán WH, Jiménez S, Arce Z, Lopez E. Clinical and serological evidence of toxocara infection in school children from Morrope District, Lambayeque, Peru. Revista do Instituto de Medicina Tropical de São Paulo.  2008; 50(2): 101–105.
    Pollack AL, Donald HRMC, Johnson RN, AI E, Irvine AR, Lahey JM, et al. Peripheral retinoschisis and exudative retinal detachment in pars planitis. Retina. 202AD;(22):719–724.
    Rodriguez A. Early pars plana vitrectomy in chronic endophthalmitis of toxocariasis. Graefe’s Arch Ophthalmol.1986; 223: 218–220.
    Rodriguez Gonzalez A. Vitrectomia en la uveitis. Medicina (Bogotá). 1989; 20: 6–12.
    Roldán WH, Cavero YA, Espinoza YA, Jiménez S, Gutiérrez CA. Human toxocariasis: a seroepidemiological survey in the Amazonian city of Yurimaguas, Peru. Revista do Instituto de Medicina Tropical de São Paulo. 2010; 52(1): 37–42.
    Roldán WH, Espinoza Y a., Huapaya PE, Huiza AF, Sevilla CR, Jiménez S. Frequency  of human toxocariasis in a rural population from Cajamarca, Peru, determined by DOT-ELISA test. Revista do Instituto de Medicina Tropical de São Paulo. 2009; 51(2): 67–71.
    Rubinsky-Elefant G, Hirata CE, Yamamoto JH, Ferreira MU. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. Ann Trop Med and Parasitology. 2010; 104(1): 3–23.
    Shields JA. Ocular Toxocariasis:A review. Surv Ophthalmol. 1984; 28(5).
    Stewart JM, Cubillan LDP, Cunningham ET. Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina. 2005; 25(8): 1005–1013.
    Werner JC, Ross RD, Green WR, Watts JC. Pars plana vitrectomy and subretinal surgery for ocular toxocariasis. Arch Ophthalmol. 1999; 117(4): 532–534.
    Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, Read RW, et al. Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists. Ophthalmology. 2012;119(6):1211–1217.

    CONTRIBUTORS

    Executive Editor:
    R. V. Paul Chan, MD, FACS, Weill Cornell Medical College, New York, New York

    Section Editor:
    Latin America:
    Sandra Belalcázar Rey, MD, Universidad del Rosario, Bogota, Colombia
    Lihteh Wu, MD, Department of Ophthalmology, Vitreoretinal Section, Instituto De Cirugia Ocular, San José, Costa Rica

    Associate Editors:
    Jeff Pettey, MD, University of Utah Department of Ophthalmology and Visual Sciences, John Moran Eye Center's Residency Program Director
    Grace Sun, MD, Weill Cornell Eye - Lower Manhattan, Weill Cornell Medical College Residency Program Director

    Assistant Editors:
    Samir Patel, BS, Weill Cornell Medical College, New York, New York
    Peter Coombs, MD, Weill Cornell Medical College; New York, New York

    Region Contributors:
    Latin America:
    Drs. Marcela Lonngi and Álvaro Rodríguez, Fundación Oftalmológica Nacional, Bogotá, Colombia

    American Academy of Ophthalmology
    P.O. Box 7424
    San Francisco, CA 94120-7424
    415.561.8500

    Copyright © 2014 American Academy of Ophthalmology®. All Rights Reserved.